Yu Du

2.8k total citations · 5 hit papers
38 papers, 1.6k citations indexed

About

Yu Du is a scholar working on Complementary and alternative medicine, Endocrinology, Diabetes and Metabolism and Pharmacology. According to data from OpenAlex, Yu Du has authored 38 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Complementary and alternative medicine, 10 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Pharmacology. Recurrent topics in Yu Du's work include Acupuncture Treatment Research Studies (12 papers), Pharmacology and Obesity Treatment (9 papers) and Diabetes Treatment and Management (9 papers). Yu Du is often cited by papers focused on Acupuncture Treatment Research Studies (12 papers), Pharmacology and Obesity Treatment (9 papers) and Diabetes Treatment and Management (9 papers). Yu Du collaborates with scholars based in China, United States and Czechia. Yu Du's co-authors include Axel Haupt, Zvonko Miličević, Sirel Gurbuz, Mark L. Hartman, Juan P. Frías, Ania M. Jastreboff, Tamer Coskun, Lee M. Kaplan, Qiwei Wu and Melissa K. Thomas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Yu Du

36 papers receiving 1.6k citations

Hit Papers

Triple–Hormone-Receptor Agonist Retatrutide for Obesity —... 2022 2026 2023 2024 2023 2023 2022 2022 2024 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
    2023 549 citations Lee M. Kaplan, Juan P. Frías et al. profile →
  2. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
    2023 232 citations Juan P. Frías, Yu Du et al. The Lancet profile →
  3. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
    2022 180 citations Tamer Coşkun, Shweta Urva et al. Cell Metabolism profile →
  4. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
    2022 130 citations Shweta Urva, Tamer Coşkun et al. The Lancet profile →
  5. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
    2024 118 citations Arun J. Sanyal, Lee M. Kaplan et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yu Du China 13 943 589 558 367 296 38 1.6k
Lisa Connery United States 5 1.3k 1.4× 889 1.5× 748 1.3× 412 1.1× 484 1.6× 10 2.1k
Marie Thi Dao Tran Denmark 6 1.5k 1.6× 1.0k 1.8× 792 1.4× 599 1.6× 597 2.0× 11 2.6k
Nadia N. Ahmad United States 12 1.5k 1.6× 1.1k 1.8× 1.0k 1.8× 490 1.3× 621 2.1× 26 2.7k
Niels Zeuthen Denmark 6 1.6k 1.7× 1.1k 1.9× 811 1.5× 655 1.8× 626 2.1× 17 2.7k
Adam Stefański United States 18 1.5k 1.6× 932 1.6× 883 1.6× 554 1.5× 561 1.9× 64 2.9k
Mathijs C. Bunck United States 10 1.6k 1.7× 1.0k 1.7× 968 1.7× 458 1.2× 578 2.0× 21 2.7k
Stephan Jacob Germany 30 1.0k 1.1× 475 0.8× 966 1.7× 805 2.2× 277 0.9× 70 2.8k
Ujjwala Vijapurkar United States 23 1.3k 1.4× 341 0.6× 353 0.6× 558 1.5× 729 2.5× 48 2.5k
Ole Kleist Jeppesen Denmark 10 2.2k 2.3× 931 1.6× 528 0.9× 1.0k 2.8× 666 2.3× 20 2.9k
Laura Fernández Landó United States 18 2.6k 2.8× 990 1.7× 763 1.4× 1.1k 3.0× 754 2.5× 52 3.2k

Countries citing papers authored by Yu Du

Since Specialization
Citations

This map shows the geographic impact of Yu Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu Du more than expected).

Fields of papers citing papers by Yu Du

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yu Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu Du. The network helps show where Yu Du may publish in the future.

Co-authorship network of co-authors of Yu Du

This figure shows the co-authorship network connecting the top 25 collaborators of Yu Du. A scholar is included among the top collaborators of Yu Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yu Du. Yu Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Shaokang, Zhe Zhang, Wei Liu, et al.. (2025). Association between obstructive sleep apnea and chronic kidney disease: A cross-sectional and Mendelian randomization study. Medicine. 104(6). e41437–e41437. 2 indexed citations
2.
3.
4.
Sanyal, Arun J., Lee M. Kaplan, Juan P. Frías, et al.. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 30(7). 2037–2048. 118 indexed citations breakdown →
5.
Urva, Shweta, Libbey S. O′Farrell, Yu Du, et al.. (2023). The novel GIP , GLP ‐1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obesity and Metabolism. 25(9). 2784–2788. 19 indexed citations
6.
Wang, Shaokang, Huiyan Shi, Xin Yan, et al.. (2023). Application and underlying mechanism of acupuncture for the nerve repair after peripheral nerve injury: remodeling of nerve system. Frontiers in Cellular Neuroscience. 17. 1253438–1253438. 15 indexed citations
7.
Bénichou, Olivier, Tamer Coşkun, Malgorzata D. Gonciarz, et al.. (2023). Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist. Cell Metabolism. 35(2). 274–286.e10. 52 indexed citations
8.
Deng, Shizhe, et al.. (2022). Revealing the Neuroimaging Mechanism of Acupuncture for Poststroke Aphasia: A Systematic Review. Neural Plasticity. 2022. 1–23. 14 indexed citations
9.
Zhang, Qiang, Qi Zhao, Miao Liu, et al.. (2022). Manual Acupuncture or Combination of Rehabilitation Therapy to Treat Poststroke Dysphagia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Evidence-based Complementary and Alternative Medicine. 2022. 1–26. 4 indexed citations
10.
Zhao, Qi, et al.. (2022). Cerebral Blood Flow Velocity Modulation and Clinical Efficacy of Acupuncture for Posterior Circulation Infarction Vertigo: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine. 2022. 1–17. 3 indexed citations
11.
Wang, Xiaoyu, Yang Chang, Hexuan Wang, et al.. (2022). Joint modeling strategy for using electronic medical records data to build machine learning models: an example of intracerebral hemorrhage. BMC Medical Informatics and Decision Making. 22(1). 278–278. 2 indexed citations
12.
Urva, Shweta, Tamer Coşkun, Yu Du, et al.. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 400(10366). 1869–1881. 130 indexed citations breakdown →
13.
Coşkun, Tamer, Shweta Urva, William C. Roell, et al.. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 34(9). 1234–1247.e9. 180 indexed citations breakdown →
14.
Xiao, Ling‐Yong, Yu Du, Huiyan Shi, et al.. (2021). Acupuncture for Hypertension in Animal Models: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine. 2021. 1–20. 5 indexed citations
15.
Zhang, Qiang, et al.. (2021). Acupuncture methods for diabetic peripheral neuropathy. Medicine. 100(10). e24967–e24967. 1 indexed citations
16.
17.
18.
Du, Yu, et al.. (2020). Efficacy and safety of acupuncture for posterior circulation ischemic vertigo. Medicine. 99(37). e22132–e22132. 2 indexed citations
19.
Jia, Peng, et al.. (2020). Manual Acupuncture or Combination with Vitamin B to Treat Diabetic Peripheral Neuropathy: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials. BioMed Research International. 2020(1). 4809125–4809125. 18 indexed citations
20.
Zhao, Xiao-Feng, et al.. (2012). Acupuncture for Stroke: Evidence of Effectiveness, Safety, and Cost From Systematic Reviews. Topics in Stroke Rehabilitation. 19(3). 226–233. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa Connery Breakdown of academic impact, for papers by Marie Thi Dao Tran Breakdown of academic impact, for papers by Nadia N. Ahmad Breakdown of academic impact, for papers by Niels Zeuthen Breakdown of academic impact, for papers by Adam Stefański Breakdown of academic impact, for papers by Mathijs C. Bunck Breakdown of academic impact, for papers by Stephan Jacob Breakdown of academic impact, for papers by Ujjwala Vijapurkar Breakdown of academic impact, for papers by Ole Kleist Jeppesen Breakdown of academic impact, for papers by Laura Fernández Landó
Rankless by CCL
2026